Drug Type CAR-T |
Synonyms CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell(St. Jude Children's Research Hospital) |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute lymphoblastic leukemia recurrent | Phase 1 | United States | 01 May 2025 | |
Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | United States | 01 May 2025 |